tirzepatide in type 1 diabetes Groundbreaking Trial Testing for Benefits of GLP-1s for Type

doi: 10.1016/j.nut.2017.06.023 39

Patients should be encouraged to report all symptoms to their trial coordinator or supervising clinician, as this contributes to the broader evidence base needed for regulatory assessment

Real-time logging immediately after eating improves accuracy and helps recognize satiety signals before overeating, as tirzepatide's delayed gastric emptying can cause sudden fullness

E.StringerK

Common schedule: Starting dose: 0.25 mg weekly Increase every 4 weeks Maintenance: up to 2.4 mg (Wegovy) How to take: Same day each week With or without food Injection sites: abdomen, thigh, upper arm Side Effects of Semaglutide Common: Nausea Vomiting Constipation Diarrhea Decreased appetite Monitoring: Patients are monitored for: tolerance weight loss progress overall health Semaglutide vs Tirzepatide Semaglutide targets GLP-1 receptors, while tirzepatide targets both GLP-1 and GIP